Replies to post #22091 on RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

More importantly, go back to where you started investing in this, ie. 2, 5 or 10 years ago. That is what matters.

Overall, you would have to say it is ugly all around, no matter what industry or field. At least with blow-ups, we [bio investors] should be less surprised. After all, we invested in biotech--it's to be expected. Be it bad luck, bad management, bad policy-making, bad IP, or just bad times, we know the risk is substantial here. We voice our concerns, maybe foolishly dump some more money into it, then move on. This is not predictable, blue-chip style business, reliable and steady, only to turn out to be a big deception. No, we are willingly and knowingly deceived.

And as far as technicals are concerned right now--forget about it--they vanished with the fundamentals. Anything goes everyone. Darwinism days again.

Other than that, with two amazing children at 5 and 2 1/2 years of age, the last five or so years have been the best in my life. Screw the government and pseudo-capitalism, love the family.

Have a nice weekend.

[horselover45]

Just one question,

Are you still mad about all the good things that you could have got into a couple of months ago?
Or are you happy where you are now??

Cheers,
Andy C.
O.T.If my Ducks can score with less then I second left in the game Cortex can come through before time runs out.

[neuroinv]

An interesting hypothesis, so I checked it out. Of the 27 CNS companies I tracked across the full two year period (almost 2 years, starting Jan 1 2007) Cortex placed ninth in price performance. Eight were better, 18 worse. When looking at the mean, its decline of 62.4% was bad, but the mean drop of the entire CNS group was 70%.

So if anything: over a 2 year period, Cortex's price performance was slightly better than the appallingly bad mean performance of its peer group. For whatever that's worth.

The numbers would thus suggest that it is not actually "ugly in comparison to other CNS stocks" over that timeframe. The overall sector--yes, that's been ugly.

NeuroInvestment